DRGT's novel Abiraterone Acetate composition - an opportunity for dose reduction and increased efficacy in prostate cancer
SWATAR, MALTA--(Marketwired - Dec 9, 2016) - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-45 program, a new composition of Abiraterone Acetate - a major drug in the fight against metastatic, castration- …